In situ Fourier transform infrared analysis of live cells' response to doxorubicin  by Fale, Pedro L. et al.
Biochimica et Biophysica Acta 1853 (2015) 2640–2648
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrIn situ Fourier transform infrared analysis of live cells' response
to doxorubicinPedro L. Fale, Ali Altharawi, K.L. Andrew Chan ⁎
Institute of Pharmaceutical Science, King's College London, SE1 9NH, UK⁎ Corresponding author.
E-mail address: ka_lung.chan@kcl.ac.uk (K.L.A. Chan).
http://dx.doi.org/10.1016/j.bbamcr.2015.07.018
0167-4889/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 22 April 2015
Received in revised form 8 July 2015
Accepted 26 July 2015
Available online 29 July 2015
Keywords:
Living cells
Chemotherapy
Drug resistance
Multi-bounce ATR
Drug screening
Infrared spectroscopyThe study of the response of cancer cells to chemotherapy drugs is of high importance due to the speciﬁcity of
some drugs to certain types of cancer and the resistance of some speciﬁc cancer types to chemotherapy drugs.
Our aim was to develop and apply the label-free and non-destructive Fourier transform infrared (FTIR) method
to determine the sensitivity of three different cancer cell-lines to a common anti-cancer drug doxorubicin at dif-
ferent concentrations and to demonstrate that information about themechanism of resistance to the chemother-
apy drug can be extracted from spectral data. HeLa, PC3, and Caco-2 cells were seeded and grown on an
attenuated total reﬂection (ATR) crystal, doxorubicin was applied at the clinically signiﬁcant concentration of
0.1–20 μM, and spectra of the cells were collected hourly over 20 h. Analysis of the amide bands was correlated
with cell viability, which had been cross validatedwithMTT assays, allowing to determine that the three cell lines
had signiﬁcantly different resistance to doxorubicin. The difference spectra and principal component analysis
(PCA) highlighted the subtle chemical changes in the living cells under treatment. Spectral regions assigned to
nucleic acids (mainly 1085 cm−1) and carbohydrates (mainly 1024 cm−1) showed changes that could be related
to the mode of action of the drug and the mechanism of resistance of the cell lines to doxorubicin. This is a cost-
effective method that does not require bioassay reagents but allows label-free, non-destructive and in situ anal-
ysis of chemical changes in live cells, using standard FTIR equipment adapted to ATR measurements.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chemotherapy is one of the main treatments of cancer. However, as
cancer cells can be sensitive or resistant to chemotherapy agents, drug re-
sistance is one of themajor obstacles for a successful treatment. It is impor-
tant to develop methodologies to evaluate the interaction of cancer cells
with chemotherapy drugs so that the mechanism of drug action and
drug resistance can be better understood for the development of more ef-
fective drugs. Knowing the response of cancer cells to chemotherapy drugs
may also allow medical practitioners to make an informed choice for the
most suitable drugs for each individual patient. Ideally, the analysis meth-
od would allow a fast and effective prediction of the sensitivity of cancer
cells to drugs, as well as provide information on the mechanism of action
of the drug or the resistance to it at a low running cost.
Fourier transform infrared (FTIR) spectroscopy is a non-destructive
and label-free technique that provides data related with the chemical
composition of the samples under analysis. It is increasingly becoming
an important analytical tool for biomedical research [1]. The FTIR spectra
of human cells are typically dominated by the absorbance due to their
content in proteins, lipids, carbohydrates, nucleic acids and. This is an open access article underphosphorylated compounds. Subtle differences in cell spectra have been
used to distinguish cells in different stages in the cell cycle [2], apoptotic
cells [3] or cell lines [4,5], to identify cancer cells [6], and to predict the ag-
gressiveness of cancer cells [7]. Several studies have shown a relationship
between the mode of action of chemotherapy drugs and changes in FTIR
spectra of dried cells [8–10], as well as differences in FTIR spectra of drug-
resistant and drug-sensitive cells [11–13]. In these studies cells were
treatedwith amildly cytotoxic or cytostatic concentration of drug, gener-
ally the IC50 value for the drug toxicity, andwere then collected and dried
prior FTIR analysis, as water causes a strong interference in FTIR analysis.
The drying process however may cause alterations or artefacts. Also, cells
are generally harvested with trypsin, including in some live cell studies
[14]. Trypsinising cells has been shown to change the protein composition
in the plasmamembrane, as well as regulating apoptosis related gene ex-
pression [15]. After trypsinisation the cells may recover after a few hours
inmedium [15], but inmost studies the cells are resuspended in isosmotic
saline solution and are not allowed to settle before analysis even though
signiﬁcant differences in cell spectra have been previously reported. The
trypsinisation and drying processes may mask or eliminate biochemical
differences caused by the treatment with chemotherapeutical agents.
Another approach is to measure living cells with FTIR while they are
still attached to a substrate to mimic the environments in most in vitro
cell studies. This can be achieved by using the attenuated total reﬂectionthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. ATR element and cell culture setup for live cells' FTIR measurement.
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medium and allowed to reach conﬂuence on the measuring surface of
the ATR element. A number of previous work had demonstrated that
this can be a powerful method to study living cells including study of
cell death [16] cell activation [17,18], differentiation [19], cell adhesion
[20,21], growth inhibition [22], and drug accumulation [23]. Using this
method, only the attached live cells are measured with no signiﬁcant
contribution from themedium above the cell because the depth of pen-
etration of themeasurement is relatively small, typically of 2–3 μm from
the surface of theATR element. This is smaller than the thickness of a liv-
ing cell. Note that the region of the cell that is closer to the ATR elementFig. 2. Effect of the addition of 20 μMdoxorubicin to FTIR spectra of HeLa cells. (A) FTIR spectra o
(1645 cm−1), amide II (1550 cm−1) and phosphate mainly from the DNA backbone (1085 cm−
rubicin was added (intensity at time 0 = 100%), plotted together with the cell viability by thewill contributemore to the absorbance than the region of the cell that is
further away from the ATR element such that there is an opportunity to
proﬁle the chemical difference along the thickness of the cell [24,25].
Here we propose to apply the ATR FTIR method, for the ﬁrst time, to
measure the effects of chemotherapy drug doxorubicin in three different
human cell lines at different drug concentrations, in situ, using settled live
cells in culture to focus on the biochemical alterations caused by the drug.
The three different cell lines were chosen with different degrees of resis-
tance to the drug to demonstrate that ATR FTIR can be a fast and cost ef-
fective method to determine the sensitivity of cancer cells to drug and at
the same time providing information on the mechanism of drug resis-
tance. We have validated the drug sensitivity results using standard
MTT assays as well as complementary ﬂuorescence measurements.
2. Materials and methods
2.1. Multi-bounce ATR FTIR accessory
A temperature controlled multi-(i.e. 10) bounce ATR accessory
trough plate (HATR, Pike technologies) and a 45° ZnS ATR element
(80mm×10mm×4mm, Crystran Ltd., UK)were used. Thepath length
in the living cells produced from this accessory is approximately 20–f HeLa cells in the 24 h following the addition of doxorubicin, (B) intensities of the amide I
1) from the moment the cells were seeded, normalised at the intensity value when doxo-
MTT assay.
Fig. 3. Effect of the addition of 1 μMdoxorubicin to the amide II bands of the FTIR spectra of
HeLa, Caco-2, and PC3 cells. Intensities of the amide II bands (1550 cm−1) were standard-
ized at the intensity value when doxorubicin was added (intensity at time 0 = 100%),
plotted together with the cell viability by the MTT assay. Amide II intensity of PC3 cells
is signiﬁcantly different from the other 2 cell lines from hour 8, while Caco-2 and HeLa
are signiﬁcantly different from hour 18 (P b 0.05).
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measurement area of ~500 mm2 where the live cells can attach and
be measured.
2.2. Live cell preparation
HeLa (ATCC#CCL-2), Caco-2 (ATCC#HTB-37), and PC3 (ATCC#CRL-
1435) were maintained in T25 cell culture ﬂasks using RPMI medium
supplemented with 10% FBS and 2 mM L-glutamine, in a 5% CO2 envi-
ronment at 37 °C. The cells were trypsinised and harvested when they
reached ~80% conﬂuence. The cells were then centrifuged into a pellet
and re-suspended in L15 medium (Sigma Aldrich) supplemented with
10% FBS, 2mM L-glutamine, 100 U/mL penicillin, and 100 U/mL strepto-
mycin. L15 was used during the ATR measurement to allow closed
chamber culturing with air as the gaseous phase. The cell suspension
was diluted in medium to reach a cell density of ~1.2 × 106 cell per
mL and 2.5 mL of the resulting cell suspension (i.e. ~3 million of cells)
was seeded directly onto the multi-bounce, temperature controlled
ATR trough which was then sealed and maintained at 35 °C, covered
with a lid (also temperature controlled at 35 °C) to prevent evaporation
(see Fig. 1). After incubating overnight, the relatively high cell seeding
density ensured the conﬂuence (N90%) of cells adhered to the measur-
ing surface, without piling on top of each other. The attachment of cells
and conﬂuencewere veriﬁed using reﬂective opticalmicroscope. Exper-
iments were conducted when the change in the spectrum of cells was
stabilised and a steady but small increase in the absorbance (b1% in-
crease per hour) of the cells was established.
2.3. FTIR measurement of samples
Continuous scan FTIR spectrometers (Frontier, Perkin Elmer Ltd., UK)
ﬁtted with a room temperature deuterated triglycine sulfate (DTGS) de-
tector was used to acquire the IR spectra. The cells on the ATR element
were exposed to 0.1, 1 or 20 μM of drug by adding the appropriate
amounts of a 1 mM solution (in L15 medium) of doxorubicin (Sigma
Aldrich) to the cell culture on the troughplate,which has a volume ofme-
dium of 2.5 mL. The cells exposed to doxorubicin were measured using
the DTGS detector with a scanning time of 11 min. A spectrumwas mea-
sured every 20min. All measurements were acquiredwith a spectral res-
olution of 8 cm−1 and a spectral range of 2000 to 900 cm−1 and amirror
speed of 0.2 cm/s. The strong Norton-Beer apodization function and self-Fig. 4.Difference spectra taken hourly during the 20 h following the addition of 1 μMdoxorubic
Arrows point the sequence from 2 h to 20 h. (D) spectrum of glycogen 10 mg/mL.phase correction were chosen for the process of the interferogram. Spec-
tra were analysed without further data retreatment. The Spectrum 10
software (Perkin Elmer Ltd., UK) was used for all data processing. All ex-
periments were done in triplicate, as well as controls in which medium
with the sameproportion ofwaterwas added to the cells instead of doxo-
rubicin solution. Full spectra of the cells were obtained using as back-
ground the spectrum of culture medium, while difference spectra were
obtained using as background the spectrum of the cells immediately
after the drug was applied (time 0 hour).
2.4. Fluorescence measurement of intracellular doxorubicin concentration
Doxorubicin was quantiﬁed with an adaptation of a method for 96-
well plates [26] to 12-well plates to increase the volume of cells, reduc-
ing the error of the method. Cells were seeded in 12 well plates, in sim-
ilar conditions as to the ones used for the ATR-FTIR experiments, using
the same medium and cell density (approx. 1 million cells/well). The
cells were incubated at 37 °C till settling and reaching conﬂuence. Doxo-
rubicin was added at a concentration of 1 μM. At times 0, 4, 8, 16, and
24 min after the addition of doxorubicin the cells were washed three
times with PBS, resuspended in 500 μL of 50% MeOH/H2O, sonicated
5 × 10 s, centrifuged 10 min at 5000 g, and the supernatant was
analysed by ﬂuorimetry with a ﬂuorimeter CytoFluor® series 4000
multiwell plate reader, using the 485/20 ﬁlter for excitation and 590/
30 ﬁlter for emission, in agreement to the ﬂuorescence characteristics
of doxorubicin [27]. The extraction step was done to avoid artefacts
due to cell components such as proteins and DNA, and methanol was
chosen due to the high recovery of doxorubicin previously reported
[28]. This was conﬁrmed by spiking collected cells with 5 μMdoxorubi-
cin and performing the extraction and measurement using methanol
and water (in triplicate). The amount detected was 97.6 ± 0.7% using
methanol solution and 38.5±8.9% usingwater, compared to a standard
solution in 50%MeOH/H2O, conﬁrming the high recovery and precision
of themethanol extraction as previously reported [28]. This control also
shows that by using methanol extraction there are no interferences in
the ﬂuorescence measurements due to quantum yield changes.
A doxorubicin calibration curve was built by measuring simulta-
neously standard solutions at the concentrations of 0, 0.1, 0.5, 1, 5, 10,
20, and 100 μM in the same conditions. The intracellular volumewas cal-
culated by adapting a method by Armbruster et al. [29]. In brief, the cells
were centrifuged at 600 g for 10 min, the supernatant was measured by
weight and discarded and the pellet was weighed (the centrifuge tubes
had been previously weighed). The volume of the cells was calculated
from the weight and known density of the cells, 1.0 g/cm3 [30]. The vol-
ume of the cells was conﬁrmed by the volume of the cell suspension be-
fore centrifuging and the volume of discarded supernatant.
2.5. Determination of cell viability
Cell viability was determined using theMTT assay [31]. Brieﬂy, 5000
cells/well were seeded 96 well plates and allowed to grow for 48 h at
37 °C, 5% CO2 until a comparable conﬂuence to the ATR FTIR experiment
was observed in thewells. Themediumwas then replaced by freshme-
diumcontaining1 or 20 μMdoxorubicin and the cells were further incu-
bated for the time corresponding to the time point of the assay. The
medium was then discarded and replaced by medium containing
0.5mg/mL ofMTT. After 2 h incubation, theMTT solutionwas discarded
and 200 μL/well of isopropanol were added. The absorbancewas read at
570 nm,with reference at 630 nm, in a SpectraMAX 190multiwell plate
reader. The percentage of viability was calculated by comparison to a
control where medium was applied instead of doxorubicin solution.
For all assays 3 × 8 replicates were done.in to (A) HeLa, (B) PC3, and (C) Caco-2 cells and their corresponding results from the PCA.
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Microsoft® Excel 2010 was used and the results were expressed as
means ± standard deviation. Additional analysis of variance (ANOVA)
was performedwith P= 0.05. PCAwas carried out using in-house soft-
ware developed for analysis of spectra for a previous study [32], using
the python programming language with numpy and scipy for calcula-
tions, and matplotlib for visualization. Spectra were truncated to
2000 cm−1 and 900 cm−1wavenumber followed by baseline correction
based on wavenumbers 1990, 1797, and 940 cm−1 using the Spectrum
10 software (Perkin Elmer) before the PCA.
3. Results and discussion
A typical set of ATR FTIR spectra of the living HeLa cells after the ad-
dition of doxorubicin are shown in Fig. 2A. The spectrumof the cells that
had just exposed to the doxorubicin shows a strong absorbance of a typ-
ical spectrum of cells with the amide II band reaching nearly 0.3 and a
peak to peak noise level in the 1900 to 1800 cm−1 region of
b3 × 10−5 such that the signal to noise ratio (SNR) is N104. The results
demonstrated the high quality of the acquired data despite of the high
water content of the live cell sample. A plot showing the normalised ab-
sorbance (peak height) of amide I at 1645 cm−1, amide II at 1550 cm−1,
and the phosphate bands at 1085 cm−1 from the point of seeding to the
cells reaching conﬂuent and after the addition of drug is shown in
Fig. 2B. The absorbance (peak height) of the amide I at 1645 cm−1,
amide II at 1550 cm−1, and phosphate mainly from the DNA backbone
at 1085 cm−1 were normalised as 100 when the cells had already
reached the plateau (conﬂuent), 20 h after seeding, and the drug was
applied. The ﬁrst spectrum after seeding HeLa cells on the ATR crystal
showed absorbance close to 0, and from then peaks corresponding to
the cells start increasing in absorbance and reached the plateau in
b20 h. After the addition of 20 μM doxorubicin to the medium, which
is referred as time 0 h, the absorbance of all major peaks of the cells in-
cluding the amide I and II and phosphate peaks decreases following a
sigmoid curve in the next 24 h (Fig. 2B). Interestingly, there is no signif-
icant difference between the rates of decrease between all major peaks,
suggesting thewhole cell absorbance is decreasing.While live cells con-
tain a lower concentration of water than themedium, using plainmedi-
um as the background could result in an overcompensation of water in
the amide I regionwherewater has strong absorbance. However, the re-
sult shows that it did not have signiﬁcant effect in this particular analy-
sis. The reduction in the total cell absorbance upon treatment of drug
can be a result of apoptosis leading to a lost in cell integrity, cell content,
and cell attachment [33]. The results from a separate independent MTT
assay carried out under similar conditions as the FTIRmeasurement are
shown on the same plot (Fig. 2B). The MTT assay is widely used toFig. 5. Quantiﬁcation of the intracellular concentration of doxorubicin by ﬂuorescence
after application of 1 μM of the drug to the culture medium in HeLa, Caco-2, and PC3
cells. Values from the 3 cell lines are signiﬁcantly different at 120 min (P b 0.05).determine toxicity of doxorubicin (for instance, [34]). TheMTT assay re-
sults show a clear correlation between the decrease in FTIR absorbance of
these peaks and the viability of the cells. However, the FTIR measurement
shows a clear drop in the absorbance in the ﬁrst 4 h after the addition of
drugwhile theMTTassayhas showna4-hourdelay in thedrop inviability.
This suggests that the FTIR measurements produce an earlier detection of
the cellular response to the 20 μMdoxorubicin than theMTT assay, show-
ing theweakening of the cells' adherence to the substrate before the com-
plete loss of bioactivities and detachment. While apoptosis of living cells
using FTIR was shown before [16,33,35], it is the ﬁrst time that FTIR data
is directly compared to an orthogonalmethod,MTT assay. The result dem-
onstrated that the FTIR method can be used to assess the viability of the
cells, with an error comparable to the MTT assay, the most used method
to quantify viability and test cytotoxicity of drugs. The non-destructive na-
ture of FTIR measurement means that a time series measurement can be
made on the same batch of live cells which is in contrast to the different
batch of cells used at each time point measured in the MTT assay. The in-
terval in the FTIRmeasurement shownwas 11min but a single FTIRmea-
surement can be captured in less than a few seconds at a lower SNR.With
the high SNR demonstrated in the current measurement, there is a poten-
tial to offer much greater temporal resolution for studying dynamic sys-
tems that are otherwise difﬁcult to be analysed using an MTT assay.
Twenty micromolar was ﬁrst chosen due to the clear loss of viability
of the HeLa cells at this drug concentration. However, the therapeutic
concentration of doxorubicin in the bloodstream is approximately
1 μM [36], and so this concentration was applied to the HeLa cell line
and compared to other cell lines that are known to resist doxorubicin
at this concentration (PC3 and Caco-2). Fig. 3 shows the correlation be-
tween the absorbance of the amide II peaks, representing the total pro-
tein in the cell, and the cell viability viaMTT assay as a function of time.
It can be observed that after 20 h in contact with 1 μM doxorubicin the
three cell lines presented signiﬁcantly different viability and the results
from FTIR measurements and MTT assays show remarkable similarity.
This demonstrates that the FTIR measurement can be used to assess
the viability of cell for at least three different cell lines treated in doxo-
rubicin. The highest decrease in viability was observed for HeLa cells,
followed by Caco-2 and PC3. At this lower concentration of drug, the de-
crease in absorbance of HeLa cells shown in Fig. 3 is slower than the re-
sult obtained when it was treated with 20 μM, which is expected. PC3
cells showed no signiﬁcant decrease in viability proving to be the
most resistant to doxorubicin of the three cell lines tested.
Apart from the total protein content as represented by the amide II,
difference spectra of the 20 h after the application of doxorubicin were
analysed to observe the chemical changes occurred from the application
of the drug. These difference spectra were obtained using the spectrum
of the cells as background at the moment of application of the drug
when the cells had already reached conﬂuent and still fully viable.
Fig. 4A–C shows the difference spectra and their corresponding PCA
analysis of HeLa, PC3, and Caco-2, respectively, after the application of
1 μM doxorubicin. HeLa cells present a decrease in cell components
that resembles the spectrum of a cell, which is similar to the result
when the cellswere treatedwith 20 μM, suggesting that cells aremainly
dying and detaching from the ATR crystal as all the absorbance due to
their components are decreasing in the same proportion. This is also
reﬂected in the PCA result where principal component 1 (PC-1) de-
scribed 100.0% of the total variancewhose the loading shows a close re-
sembles of the spectrumof the living cells. Although PC-1 dominates the
changes in the difference spectra, it is still possible to observe the small
changes from PC-2 such as the negative peaks at ~1600 cm−1 and
~1400 cm−1 (marked with asterisks), which are typical peaks for me-
tabolites containing carboxylate. Note that the transition of the cells
can be traced from the bottom right of the PCA score plot to the top
left allowing the order of events in the cells to be tracked after the treat-
ment of drug. PC3 cells showed positive amide bands, 1645 and
1550 cm−1, from the moment the drug was applied suggesting that
the culture continued to grow in the ﬁrst hours of the assay (Fig. 4B).
Fig. 6. Difference spectra taken hourly during the 20 h following the addition of 0.1 μM doxorubicin to (A) HeLa, and 20 μM doxorubicin to (B) PC3, and (C) Caco-2 cells and their corre-
sponding results from the PCA. Arrows point the sequence from 2 h to 20 h.
2645P.L. Fale et al. / Biochimica et Biophysica Acta 1853 (2015) 2640–2648
2646 P.L. Fale et al. / Biochimica et Biophysica Acta 1853 (2015) 2640–2648This immediate increase in the amide bandswas followed by a slight de-
crease in the later hours but never reached negative intensities as can be
seen by the last spectra measured (lightest spectra in Fig. 4B). However
this growthwas not followed by a proportional increase in the intensity
in the 1085 cm−1 region, attributed mostly to nucleic acids. The de-
creases in the 1085 cm−1 and 1240 cm−1 regions suggest that the
amount of nucleic acids or triphosphate compounds in the cells may
be lower relative to the protein content than before the addition of
doxorubicin. This is also conﬁrmed from the PCA results (Fig. 4B)
where PC-1, the dominating variant (94.8%), shows negative amide
peaks with a negative score. Note that PC-2 (4.8% of the variance),
apart from highlighting the change in the 1085 cm−1 and 1240 cm−1
regions with negative peaks, also shows positive peaks at 1600 cm−1
and 1400 cm−1 which suggests that there is a change in both the car-
boxylate metabolites and nucleic acids or triphosphate compounds in
the cell which such changes in carboxylate peaks were not easily no-
ticed from the original spectra. Caco-2 cells showed a smaller decrease,
compared to HeLa, in all major peaks of the various cell components.
However, a relatively large decrease in the ﬁrst hours was found in
the region of 1024 cm−1, which seemed to be predominant throughout
the 20 h and led to the different shape of the spectra in the phosphate/
carbohydrate region of 950–1200 cm−1. A closer examination of the re-
duction in absorbance in this region has shown that the spectral fea-
tures resemble the spectrum of glycogen, which is shown in Fig. 4D. It
is not surprising that changes in glycogen content could be detected in
Caco-2 cells as it is known to be accumulated in high amounts in these
cells as storage material to obtain energy [37]. A depletion of glycogen
was also observed in a previous FTIR imaging study when SKOV3 cells
were starved of nutrient [33]. Other authors have demonstrated that re-
sistance by efﬂux of doxorubicin is glucose-dependent, being not only
promoted by the supply of glucose [38], but also abolished upon glucose
starvation [39], causing loss of resistance. Glycogen depletion in Caco-2
cells undergoing higher than normal rates of glucose consumption has
been reported by many authors [40,41]. The PCA results are in good
agreement with the observation made to the raw difference spectra
where Fig. 4C shows that PC-1 (99.6% of the variance) is showing the
protein amide bands and the glycogen bands. However, PC-2 although
accounts for only 0.3% of the variance, shows negative bands in
1080 cm−1 and 1240 cm−1 regions which again were not easily ob-
served from the original spectra.
To understand the correlation between the response of the three
types of cells to doxorubicin and resistance, the intracellular amount
of the drug was quantiﬁed using ﬂuorimetry after 4, 20, 60, and
120 min exposing to 1 μM of the drug. The results are shown in Fig. 5.
All cells presented an intake of the drug to intracellular concentrations
higher than the culture medium, which may be due to the previously
observed partitioning effect attributed to the intercalation of doxorubi-
cinwith theDNAmolecule and consequent accumulation in the nucleus
of the cell [42]. HeLa presented the highest intake of the drug reaching
concentrations more than 7× higher than the applied after 120 min.
Caco-2 and PC3 also showed an accumulation to concentrations higher
than the external but to amuch lower extent thanHeLa and a lower rate
of intake, suggesting that a control of the diffusion of the drug to be in-
tercalated to the DNA may be associated with doxorubicin resistance
shown by these 2 cell lines. In fact, other reports have shown that doxo-
rubicin is a substrate of themembrane efﬂux transporter P-glycoprotein
(Pgp), which is considered themain cause of the doxorubicin resistance
of PC3 cells [43] and Caco-2 cells [44]. The transport through Pgp is
energy-dependent and therefore the depletion of the glycogen storage
observed in Caco-2 may be due to the need of energy for the efﬂux of
doxorubicin.
To further investigate the cells' response to doxorubicin at different
drug concentration levels, 20 μMwas applied to themore drug resistive
Caco-2 and PC3 cells and 0.1 μMwas applied to the more drug sensitive
HeLa cells (Fig. 6). In the presence of a 10× lower amount of doxorubi-
cin, HeLa cells (Fig. 6A) showed an increase in the amide bands,suggesting growth of the culture,whichwas not followed by an increase
in the intensity in the nucleic acid region (1085 cm−1), a response sim-
ilar to PC3 treated with 1 μMdoxorubicin (Fig. 4C). The PCA of this data
set shows similar trend to the observation made to the raw difference
spectra. PC-1 (97.5% of the variance) is showing negative protein
amide bands with a negative PCA score (the protein bands were in-
creasing) and the PC-2 (1.8% of the variance) shows a positive DNA
bands at 967 cm−1, 1085 cm−1, and 1225 cm−1 with, most of the
time, a negative PCA score suggesting that the DNA was decreasing
most of the time except at time point 4 and 5 (circled on the PCA
score plot) where the DNA bands were increasing. Note that the PCA
highlighted the temporal increase in the DNA absorbance at time points
4 and 5, which represent the 4th and the 5th hour after the addition of
the drug, that would not be captured by traditional biochemical assays.
The result of this temporal change in the DNA suggests that there is a
transient process in the HeLa cell that can be related to the overall
chemical process inside the living cells in response to the presence of
drug in the medium. The PC-2 loading shows a particular difference
when compared to the PC-2 loading of HeLa cells treated in 1 μM of
drug (Fig. 4A). A strong decrease in the DNA bands relative to the pro-
tein band was not observed in Fig. 4A but was clearly shown in
Fig. 6A. This result suggested that the HeLa cells may have different re-
sponses when treated in 0.1 μM and 1 μM of drug.
PC3 and HeLa cells with 1 μM and 0.1 μM doxorubicin, respectively,
showed a decrease in the nucleic acid region while an increase was ob-
served in the protein regions (Figs. 4B and 6A). Possible explanations for
the observed decrease in nucleic acid bands include that there is a
change in conformation of the DNA with the presence of drug or the
cell entered a different phase of the cell cycle. Fig. 2 has already
shown that the phosphate band did not change in the control sample
demonstrating that the cell cycle did not contribute to the change, pos-
sibly because the cells were not synchronised and therefore the effect of
the different phases of the cell cycle were averaged and not shown. In
terms of DNA conformation, Walsh et al. had shown in their human in-
testinal crypts study that the DNA νsym(PO2−) band absorbance in-
creases in the region where putative stem cells are located [45].
Whelan et al. had shown in a DNA hydration–dehydration study that
upon dehydration, the DNA of the cells would change from the B-form
structure to the A-form structure resulting in an overall broadening, a
loss of intensity and a shift of the peak position from 1225 cm−1 to
1240 cm−1 in the νsym(PO2−) band [46]. However, a shift of the peak po-
sition would lead to a derivative-shaped band in the difference spec-
trum shown in Figs. 4 and 6 which is not observed. The PC loadings
also show that the DNA νsym(PO2−) band peaked at 1225 cm−1 (PC-2)
suggesting a lost in the B-form DNA but without an increase in the
1240 cm−1 region. Furthermore, an ex situ FTIR measurement of calf
DNA solutions with doxorubicin has shown that no difference can be
observed in the DNA absorbance with and without the presence of
20 μM doxorubicin. Another suggestion is that cell culture growth still
proceeded to a certain extent even with a relative decrease in nucleic
acid content. The decrease in nucleic acidmay be due to themechanism
of action of the drug itself, which inhibits DNA replication by intercalat-
ing with the DNA molecule. Apart from the efﬂux of doxorubicin, the
higher resistance of PC3 is usually attributed to the loss of phosphatase
and tensin homolog (PTEN) activity [47], which is involved in the regu-
lation of the cell cycle. PTEN is a tumour suppressor gene and the loss of
its protein activity decreases cell death, which leads to continued prolif-
eration even when there are DNA replication perturbations as in the
presence of doxorubicin. HeLa cells, even though expressing correctly
PTEN [48], also lack other tumour suppressor gene activity [49], which
may lead to uncontrolled growth to a certain extent in conditions lead-
ing to apoptosis in normal cells.
With a higher concentration of doxorubicin, PC3 and Caco-2 cells
showed a decrease in absorbance for all peaks of the major cell compo-
nents suggesting a predominance of cell death over any changes. The
PCA of the PC3 and Caco2 cells treated in 20 μM doxorubicin shows
2647P.L. Fale et al. / Biochimica et Biophysica Acta 1853 (2015) 2640–2648generally same trend in the PC-1 and PC-2 score and loading plots. In
both cases, the PC-1 score plot in Fig. 6B and, to a less extent, 6C
shows that the value was initially negative which then increased and
become positive as a function of time suggesting that the protein
bandswere initially increased before decreasing. Apart from the general
increase in the protein major bands as marked by PC-1, both PC-2 in
Fig. 6B and C show that carboxylates (1400 cm−1 and 1600 cm−1
bands) were increasing while the DNA bands were decreasing suggest-
ing that the mechanism of action of drug on PC3 and Caco2 cells is the
same when treated in high drug concentration.
4. Conclusion
ATR FTIR spectroscopy has shown to be a valuable tool for the analysis
of living cell under treatment of anti-cancer drugs. The label-free and
non-destructive natures of the measurement avoid ﬁxation and labelling
process that might have led to artefacts. Three different cell lines, HeLa,
PC3, and Caco-2, which have different levels of resistance to a common
cancer drug doxorubicin, have been successfully tested at three different
drug concentrations (0.1 μM, 1 μM, and 20 μM). FTIR spectral data allows
in situ analysis of chemical changes in the living cells, enabling to deter-
mine cell viability and to compare the resistance of different cell lines to
the chemotherapy drug and the FTIR results were found to be consistent
with the equivalent independent MTT assays.
Difference spectra also revealed the subtle changes inside living cells
under treatment providing information about the mechanism of resis-
tance of the cells. The spectra allow the observation of the chemical
changes immediately. In this case, signiﬁcant changes to the relative ab-
sorbance of the spectral bands that have been assigned to nucleic acids
and glycogen were observed upon treatment of doxorubicin. This pro-
vided evidences for the inhibition of DNA synthesis of doxorubicin and
the signiﬁcant energy consumption of the resistive cells as a result of
the efﬂux of the drug. Application of PCA to the data conﬁrmed the ob-
servation made with the raw difference spectra. However, some spec-
tral changes highlighted by PCA were not easily observed from the
rawdata such as the changes in the carboxylate bands and some tempo-
ral events in the changes in the DNA bands. Comparison of PCA loadings
also helped to identify similarities and differences for the response of
the different cell lines treated in different drug concentrations, demon-
strating that the technique is suitable for the study of cellular response
to drug treatment and to be used as a drug screening tool.
This is a non-destructive and cost-effective method that has a low
running cost as there are no reagents required except the culture medi-
um and the drug under investigation.
We have demonstrated that this method can be a powerful tool for
drug development. It is applicable to most in vitro drug studies where
drug developers can use it as a tool to elucidate the toxicity of the
drug as well as the mechanism of action of the drug or drug resistance.
One of the key advantages of this method is that the measurement can
be made continuously to the same batch of cells with temporal resolu-
tion potentially down to less than a few seconds providing capability
to identify transient cellular events that are otherwise very difﬁcult to
capture using standard biochemical assays. The technology has the po-
tential to become a powerful tool in ﬁnding the most adequate treat-
ments for speciﬁc types of cancer.
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